
Sign up to save your podcasts
Or


This episode was released in February 2021, and is being re-shared to offer the research behind the popular weight loss drugs Ozempic and Wegovy. Northwestern's Robert Kushner, MD, discusses the drug semaglutide, typically prescribed for treatment of Type 2 diabetes and the results of the phase 3 clinical trial as a treatment for obesity with very promising results. The study was published in the New England Journal of Medicine, and in 2022, Kushner was awarded the prestigious Herbert Pardes Clinical Research Excellence Award from the Clinical Research Forum.
By Northwestern University Feinberg School of Medicine4.9
2424 ratings
This episode was released in February 2021, and is being re-shared to offer the research behind the popular weight loss drugs Ozempic and Wegovy. Northwestern's Robert Kushner, MD, discusses the drug semaglutide, typically prescribed for treatment of Type 2 diabetes and the results of the phase 3 clinical trial as a treatment for obesity with very promising results. The study was published in the New England Journal of Medicine, and in 2022, Kushner was awarded the prestigious Herbert Pardes Clinical Research Excellence Award from the Clinical Research Forum.

91,297 Listeners

21,954 Listeners

43,687 Listeners

91 Listeners

6,467 Listeners

113,121 Listeners

5 Listeners

56,944 Listeners

0 Listeners

10,331 Listeners

33 Listeners

3,051 Listeners

8,238 Listeners

29,272 Listeners

1,598 Listeners

4,294 Listeners

7 Listeners

632 Listeners

12,559 Listeners